EUROPEAN COMMISSION PUBLISHES REPORT ON EXTERNAL REFERENCE PRICING FOR MEDICINAL PRODUCTS
The report identifies the main parameters which impact the pricing and reimbursement decisions for medicinal products within external reference pricing systems. These parameters include the effects of pricing and reimbursement decisions for medicinal products taken in one EU Member State on pricing and reimbursement decisions in other EU Member States.
Based on a simulation model, the assessment identified these main parameters in all 28 EU Member States. The report also briefly examines the external reference pricing processes in non-EU countries such as Australia, Canada, Japan and Turkey.
On 26 September 2016, a new EU-US collaboration between the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) was announced. This new collaboration is ...06 October 2016
On 1 September 2016, the European Medicines Agency ("EMA") opened for public consultation a Draft revision to its Guideline on the assessment of clinical safety and efficacy in the...08 September 2016